{"organizations": [], "uuid": "afc5849a725c721de90f13c9e31d3042dae8e114", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180208.html", "section_title": "Archive News &amp; Video for Thursday, 08 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-tianjin-chase-sun-pharmaceutical-u/brief-tianjin-chase-sun-pharmaceutical-unit-receives-certificate-of-suitability-for-european-pharmacopeia-from-edqm-idUSL4N1PZ1L8", "country": "US", "domain_rank": 408, "title": "BRIEF-Tianjin Chase Sun Pharmaceutical unit receives certificate of suitability for european pharmacopeia from EDQM", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.793, "site_type": "news", "published": "2018-02-09T10:21:00.000+02:00", "replies_count": 0, "uuid": "afc5849a725c721de90f13c9e31d3042dae8e114"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-tianjin-chase-sun-pharmaceutical-u/brief-tianjin-chase-sun-pharmaceutical-unit-receives-certificate-of-suitability-for-european-pharmacopeia-from-edqm-idUSL4N1PZ1L8", "ord_in_thread": 0, "title": "BRIEF-Tianjin Chase Sun Pharmaceutical unit receives certificate of suitability for european pharmacopeia from EDQM", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "edqm", "sentiment": "negative"}, {"name": "tianjin chase sun pharmaceutical co ltd", "sentiment": "negative"}, {"name": "brief-tianjin chase sun pharmaceutical", "sentiment": "negative"}, {"name": "beijing headline news", "sentiment": "none"}, {"name": "european directorate", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 9 (Reuters) - Tianjin Chase Sun Pharmaceutical Co Ltd\n* Says wholly owned pharmaceutical unit received certificate of suitability for european pharmacopeia (CEP) from European Directorate for the Quality of Medecines(EDQM)\n* Certificate issued to etomidate manufactured by the unit and the valid period is five years\nSource text in Chinese: goo.gl/jgWS2z\nFurther company coverage: (Beijing Headline News)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "https://goo.gl/jgWS2z"], "published": "2018-02-09T10:21:00.000+02:00", "crawled": "2018-02-09T16:26:23.027+02:00", "highlightTitle": ""}